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SUMMARY
Host cell entry of vaccinia virus, the prototypic
poxvirus, involves a membrane fusion event deliv-
ering the viral core and two proteinaceous lateral
bodies (LBs) into the cytosol. Uncoating of viral cores
is poorly characterized, and the composition and
function of LBs remains enigmatic. We found that
cytosolic cores rapidly dissociated from LBs and
expanded in volume, which coincided with reduction
of disulfide-bonded core proteins. We identified the
abundant phosphoprotein F17, the dual-specificity
phosphatase VH1, and the oxidoreductase G4
as bona fide LB components. After reaching the
cytosol, F17 was degraded in a proteasome-depen-
dent manner. Proteasome activity, and presumably
LB disassembly, was required for the immediate
immunomodulatory activity of VH1: dephosphoryla-
tion of STAT1 to prevent interferon-g-mediated anti-
viral responses. These results reveal a mechanism
used by poxviruses to deliver viral enzymes to the
host cell cytosol and are likely to facilitate the identi-
fication of additional LB-resident viral effectors.
INTRODUCTION
The ultimate goal of a virus particle is to transport a replication-
competent viral genome from an infected to a noninfected cell.
This involves delivery of the genome and accessory proteins to
the cytosol or nucleus. Typically, it also requires uncoating and
decondensation of the genome as well as release of any addi-
tional factors within the virus particle. Depending on the virus,
different strategies are in place to generate favorable conditions
for replication of viral genomes, production of viral nonstructural
and structural proteins, and assembly of new virus particles. In
addition, viruses have evolved a plethora of mechanisms to sup-
press, modulate, and avoid antiviral defense mechanisms.
Vaccinia virus (VACV), the prototypic poxvirus, is a close rela-
tive of variola virus, the causative agent of smallpox (Damon,
2007). During infection, VACV produces two infectious forms,
mature virions (MVs) and extracellular virions (EVs), which
contain one or two viral membranes, respectively. In both, the
viral DNA genome is packaged within a biconcave core flanked
on two sides by structures termed lateral bodies (LBs). The
LBs are composed of protein (Ichihashi et al., 1984) and have a
roughly oblate ellipsoidal shape that fits into the concavities of
the viral core (Cyrklaff et al., 2005).
That the protein composition and function of LBs has re-
mained unclear is likely due to the complexity of poxviruses,
composed of 100 structural proteins, and the inability to purify
intact LBs from viral particles or infected cells. When the viral en-
velope is removed usingmild detergents, LBs remain associated
with cores, suggesting a coherent structure stably anchored to
the surface of the core (Easterbrook, 1966). During virus forma-
tion, cores and LBs only become visible as distinct structures
after a complex morphogenesis process (Condit et al., 2006),
which transforms an immature virion filledwith amorphousmate-
rial into an MV with two distinct core layers and LBs. This in-
volves proteolytic cleavage of core proteins and disulfide bond
formation within and between viral proteins, a process catalyzed
by viral enzymes (Senkevich et al., 2002). TheMVs generated are
exceptionally resistant to external influences, such as heat and
dehydration. They can remain infectious in biological samples
for extended times, adding to the potential danger inherent to
this large virus family (MacCallum and McDonald, 1957). The
elaborate mechanisms of uncoating and activation of the stable
‘‘spore-like’’ particles during cell entry are of particular interest.
MVs and EVs are internalized into host cells by virus-induced
macropinocytosis (Huang et al., 2008; Mercer and Helenius,
2008; Schmidt et al., 2011). For both, the final step of entry is
the release of the viral core into the host cell cytosol by a mem-
brane fusion event (Moss, 2012). In some VACV strains and
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under certain experimental conditions, fusion was also observed
at the plasma membrane (Bengali et al., 2012; Chang and Metz,
1976; Chang et al., 2010; Law et al., 2006). The disassembly of
viral cores occurs in two steps: in the first, they undergomorpho-
logical changes, expand, and take on an oval morphology
(Cyrklaff et al., 2007; Dales, 1963; Hollinshead et al., 1999). Tran-
scription of early viral genes is initiated within the core,
transcripts are released, and 80 different early proteins are
translated in the cytosol (Yang and Moss, 2009). A second
core disassembly step is the genuine uncoating process: the
viral DNA genome is released into the cytosol (Joklik, 1964a)
and the core is disassembled (Schmidt et al., 2012). This step,
needed for replication of the viral DNA, requires the expression
Figure 1. Morphological Changes during
VACV Core Activation
(A–D)WRWTMVswere bound to HeLa cells on ice
(moi 100) and cells either incubated at 37C in the
presence of ActD (5 mg/ml) for 3 hr (A) or treated
with pH 5 medium for 5 min at 37C followed by
either 30 min at 37C (B and D) or no further in-
cubation (C). Sampleswere prepared following the
protocols for epoxy embedding (A–C) or cry-
osectioning and anti-DNA immunogold labeling
(D). Typical images of thin sections are shown.
Bound MVs are highlighted with arrowheads,
cytosolic cores with arrows; Nu, nucleus. Scale
bars, 500 nm (A, B, and D, top), 100 nm (A, B, and
D, bottom), and 200 nm (C).
(E) Quantification of core length and width in MVs,
cytosolic cores, and in vitro cores (n = 100). Boxes
denote interquartile range, lines within boxes
represent the median, whiskers denote 10th and
90th percentiles, and dots show outliers.
(F and G) Representative thin sections of MVs (F)
and in vitro cores (G) prepared by cryosectioning
and anti-DNA immunogold labeling. Scale bar,
100 nm.
See also Figure S1.
of early viral protein(s) and the activity of
host factors, including the proteasome
(Joklik, 1964b; Mercer et al., 2012). Host
cell proteasomes are also required for
viral DNA replication (Satheshkumar
et al., 2009; Teale et al., 2009).
Although LBs have been visualized by
electron microscopy as distinct entities
shortly after fusion (Laliberte et al.,
2011), their fate and function after virus
entry is unknown. That LBs are not visible
on cytosolic cores indicates that the
association between the two is lost. In
this study, we used electron and fluores-
cencemicroscopy as well as biochemical
techniques to visualize core activation
and analyze the composition, function,
and fate of LBs of VACV strain Western
Reserve (WR). We identified F17, a small
phosphoprotein, as the main component
of LBs and found that at least one immunomodulatory protein,
the viral dual-specificity phosphatase VH1, is brought into cells
in LBs and released in a proteasome-dependent manner. A sec-
ond viral enzyme, the glutaredoxin G4, was also found in LBs.
RESULTS
VACV Cores Undergo Rapid Morphological Changes
Due to the rapid disassembly of incoming cores in the cytosol
(Dales, 1963), we used two strategies to enrich this virus struc-
ture for visualization in epoxy-embedded electron microscopy
(EM) samples: inhibition of early gene expression, a prerequisite
for uncoating, using actinomycin D (ActD) (Figure 1A) and low
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pH-induced fusion of MVs with the plasma membrane to syn-
chronize core release (Figure 1B; Gong et al., 1990). In both
cases, the cores observed in the cytosol were different from
cores in intact MVs. Instead of having a biconcave shape, they
were larger with an expanded oval or ellipsoidal shape (Figures
1A, 1B, S1A, and S1B). We termed this morphological change
core ‘‘activation’’. LBs, which filled the core indentations in
MVs, were no longer present.
When analyzed 5 min after acid-induced fusion at the plasma
membrane, cores released into the cytosol already exhibited the
dilated oval shape (Figure 1C). The LBs remained associated
with the fused viral membrane and were no longer attached to
the core. The images suggested that the morphological changes
in the core occurred during fusion or shortly after exposure of the
core to the cytosol and that contact between cores and LBs was
concomitantly lost.
To assure that the observed morphological changes were not
due to dehydration associated with EM sample processing, EM
samples were prepared according to the protocol established by
Tokuyasu to better preserve the hydration state of the sample
(Slot and Geuze, 2007; Tokuyasu, 1973; Figure 1D). Although
LBs could not be readily visualized, the same changes in core
morphology were observed under these conditions, indicating
that they were not an artifact of sample preparation.
To better understand the requirements of core activation and
LB disassociation, we compared cores within MVs to cytosolic
cores and cores generated in vitro by removal of the viral mem-
brane with detergent (NP-40) and a reducing agent (dithiothreitol
[DTT]) (Easterbrook, 1966; Ichihashi et al., 1984; Figures 1F, 1G,
and S1C–S1E). In agreement with the literature (Easterbrook,
1966), in vitro cores were composed of cores and associated
LBs. Visualization of LBs depended on core orientation within
the section.
We next measured the dimensions of the cores and classified
them based on shape as biconcave, oval, or intermediate (Fig-
ures 1E and S1F). CoreswithinMVs had an average central width
of 56 nm, and 60% of all cores were classified as biconcave.
Cores in the cytosol and those generated in vitro were wider
(average central width 103 and 113 nm, respectively) and mostly
classified as oval (66% and 57%of all cores, respectively). When
core volumes were approximated using the area of the cores in
sections (as described in Experimental Procedures; Cyrklaff
et al., 2007), cytosolic and in vitro cores exhibited a 1.44- and
1.78-fold larger core volume than those in an MV (1.263$106
nm3). Thus, the process of cytosolic core activation and in vitro
core generation resulted in the loss of core biconcavity, an
expansion of its central diameter, and a calculated increase in
core volume, perhaps generating space for the transcription pro-
cess. In contrast to the situation after fusion, LBs remained
attached to the core when membranes were removed artificially
using NP-40 and DTT. This suggested that membrane removal
and reduction of core proteins are sufficient to induce the
morphological changes that occur during core activation,
whereas LB disassociation requires additional cues.
Viral Core Proteins Are Reduced During Activation
As our in vitro-generated cores resembled activated cytosolic
cores and similar morphologies were observed in DTT-treated
MVs (Cyrklaff et al., 2007; Locker andGriffiths, 1999), we hypoth-
esized that core activation may involve the reduction of disulfide
bonds in viral core proteins. In support of this, two core proteins,
4a and VP8, were shown to be reduced during infection (Locker
and Griffiths, 1999). Using redox two-dimensional (2D) SDS-
PAGE (Sommer and Traut, 1974) and a combination of sucrose
gradients and reducing SDS-PAGE, we identified 13 disulfide-
bonded VACV proteins (Figure S2; Table S1). Seven have been
described as core-associated: F17 (also known as F18; see
Table S2 for nomenclature of VACV proteins), VP8, A4 (also
known as A5), 4a, 4b, and the RNA polymerase subunits
RPO132 and RPO147. F17, VP8, 4a, and 4b in MVs were disul-
fide crosslinked into high-molecular-weight complexes. They
migrated slowly into or did not enter gels when subjected to
nonreducing SDS-PAGE, but migrated as monomers after
reduction (Figure 2A). Although the majority of the reduced F17
migrated as expected for monomeric F17, at least three addi-
tional slower migrating bands were observed. Anti-hemaggluti-
nin (HA) immunoblots of WR F17-HA MVs confirmed that these
were F17 (data not shown). A4 exhibited only intramolecular di-
sulfide bonds and ran faster under nonreducing conditions,
due to the more compact structure. High-molecular-weight
complexes of RPO132 and RPO147 were confirmed by transient
expression of HA-tagged versions in infected cells (data not
shown).
To monitor the redox state of the identified proteins during
infection, MVs were bound to HeLa cells on ice and harvested
or shifted to 37C for 3 hr in the presence or absence of ActD.
Preincubation of MVs with the L1 antibody 7D11 (Wolffe et al.,
1995), which blocks core release by MV fusion (Schmidt et al.,
2011), served as a control. Cells were harvested and the viral
proteins 4b, VP8, and F17 analyzed by nonreducing or reducing
SDS-PAGE and immunoblots. Although the majority of these
proteins run as monomers upon reduction, no low molecular
weight species of F17 or 4b were detected under nonreducing
conditions when MVs were prevented from entering host cells
(Figure 2B; 0 hr and 3 hr +7D11). At 3 hr post infection, in the
absence or presence of ActD, low-molecular-weight bands of
F17 and 4b were detected under nonreducing conditions,
whereas no changes in the redox state of VP8 were seen. This
indicates that F17 and 4b are reduced after deposition of viral
cores into the host cytosol, but before early gene transcription
(i.e., a stage of infection that coincides with core activation).
During these experiments, we observed that the predominant
form of F17 was detected at 25 kDa, migrating slightly slower
than one of the minor F17 bands found in reduced samples (Fig-
ure 2A). When the redox state of F17 was followed during infec-
tion using WR F17-HA and HA antibodies, an identical F17 band
pattern was seen, ruling out that the bands were nonspecific
(Figure 2C).
F17 Is a Major LB Component
With 27,000 copies per MV (Sarov and Joklik, 1972), the phos-
phoprotein F17 is the third most abundant structural protein of
VACV (Chung et al., 2006). Although generally considered a
core protein, given that it is present in in vitro-generated cores
(Kao and Bauer, 1987; Kao et al., 1981; Sarov and Joklik,
1972), Pedersen et al. (2000) showed that F17 is absent from
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cytosolic cores. Using recombinant viruses incorporating either
an additional copy of F17 as an EGFP fusion protein or an
EGFP fusion of the core protein A4 in combination with anti-
GFP immunogold labeling (Figures S3A–S3D), we confirmed
these results (Figures 3A–3G). While 94% of cytosolic cores
were positive for EGFP-A4, only 14% were positive for EGFP-
F17. Thus, EGFP-F17 was largely absent from activated, cyto-
solic cores.
To determine if F17 was absent from cytosolic cores because
it is a LB protein, ultrathin cryosections of MVs and in vitro cores
were immunogold labeled with F17 antibodies (Figures 3H, 3I,
S3E, and S3F). Quantification showed that, on average, 2.4
and 5.2 gold particles clearly localized to LBs in MVs and
in vitro generated cores, respectively (Figure 3K). The few gold
particles that localized over the core (0.8 and 1.0 gold particle
per core in MVs and in vitro cores, respectively) were likely due
to the abundance of F17 and/or the distance between the
epitope and the gold particle. Very few gold particles were found
outside virion structures.
To verify the localization of F17 to LBs, we treated in vitro cores
with a low concentration of trypsin—amethod previously used to
remove LBs (Easterbrook, 1966; Ichihashi et al., 1984). Trypsin-
treated in vitro cores that no longer contained intact LBs were
negative for F17 (Figures 3J and S3G). This indicated that F17
labeling depended on intact LBs. While the close proximity of
LBs and cores did not allow unambiguous labeling, these results
suggested that F17 was present within LBs.
Our initial EM images showed that LBs remained at the virus-
derived membrane after acid-induced fusion of MVs (Figure 1C).
Figure 2. Disulfide-Bonded Viral Proteins
Are Reduced during Core Activation
(A) WR WT MVs were alkylated with NEM and
boiled in SDS sample buffer without or with DTT.
Protein samples were analyzed by SDS-PAGE and
immunoblot with the indicated antibodies. Arrows
indicate positions of monomeric reduced proteins.
The molecular weight marker positions are indi-
cated on the right.
(B and C) WR WT (B) or WR F17-HA (C) MVs were
bound to HeLa cells for 1 hr (moi 200) and cells
either harvested directly (0 hr) or incubated at
37C for 3 hr in the absence or presence of ActD.
7D11-neutralized MVs served as controls. Cells
were alkylated with NEM and harvested. Protein
samples were prepared in SDS sample buffer
without or with DTT and analyzed as in (A).
See also Figure S2 and Tables S1 and S2.
Five minutes post fusion, we identified
viral cores and LBs in close proximity to
the plasma membrane (Figures 3L and
S3H). More importantly, the distance be-
tween cores and LBs was sufficient to
unambiguously determine that F17 label-
ing was exclusively associated with LBs.
To study the fate and localization of
F17 and viral cores by fluorescence
microscopy, we constructed a virus (WR
EGFP-F17 VP8-mCherry) that incorporated EGFP-F17 and an
mCherry fusion of a bona fide core protein, the DNA-binding pro-
tein VP8 (encoded by the L4R gene [Yang et al., 1988]; see Fig-
ure S4 for details). Successful incorporation of both proteins into
MVs was confirmed by fluorescence microscopy (Figure 4A) and
immunoblot analysis (Figures S4C and S4D). Both EGFP-F17
and VP8-mCherry remained associatedwith in vitro cores, as ex-
pected of core and LB components (Figure S4B).
When HeLa cells were infected with WR VP8-mCherry EGFP-
F17 for 3 hr in the presence of ActD and analyzed by confocal
microscopy, stabilized cytosolic cores did not contain EGFP-
F17 (Figure 4C). Conversely, almost all VP8-mCherry-containing
cores colocalized with EGFP-F17 in controls where MVs were
bound to HeLa cells in the cold to prevent fusion (Figure 4B).
Collectively, these results confirmed that F17 was part of the
LBs and not present in cytosolic cores after activation.
LBDisassembly Is Aided byCellular ProteasomeActivity
Our EM data suggested that, immediately after fusion, LBs
dissociated from cores as distinct structures (Figure 1C), yet
we rarely observed intact LBs within host cells by EM at later
times. While in the presence of ActD, a few EGFP-F17 punctae
corresponding to LBs could be detected; they were far outnum-
bered by fluorescent cores (Figure 4C). This suggested that free
LBs were unstable after delivery to the cytosol and that their
disappearance did not depend on early viral gene expression.
To determine if LBs were dispersed or degraded, we used
WR F17-HA and tested whether the abundant LB protein F17
was lost from cells in a proteasome-dependent manner. WR
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F17-HA MVs were bound to HeLa cells in the cold and the cells
harvested directly or after acid-induced fusion and 2 hr at 37C in
the absence or presence of the proteasome inhibitor MG-132
(Rock et al., 1994). ActD was present to prevent viral gene
expression. Bound virus particles were removed by trypsin
digestion and the cell-associated levels of F17-HA, and the
core proteins, VP8 and 4b, were determined (Figure 4E).
In samples harvested 2 hr after fusion, the levels of cell-asso-
ciated F17 were 3-fold higher in the presence of MG-132, indi-
cating that F17 exposed to the cytosol was degraded by host
cell proteasomes. As expected, due to core stabilization by
ActD, levels of VP8 and 4b were largely unchanged in the pres-
ence or absence of MG-132. In nonsynchronous infection exper-
iments, in which fusion was expected to occur after endocytosis,
cell-associated F17 was also stabilized in the presence of pro-
teasome inhibitors 3 hr post infection (Figure S4E). Given that
F17 in MVs was detected in immunoblots as multiple bands
shifted by ca. 8 kDa, we wondered if the F17 packaged into
virions was ubiquitinated. Mass spectrometry-based prote-
omics was applied to analyze F17-HA immunoprecipitated
fromMVs solubilized in 1%SDS and 50mMDTT.We confidently
identified 86 peptides of F17-HA, representing a sequence
coverage of 97% (Figure S4F) as well as peptides of ubiquitin
(data not shown). Several identified peptides of F17 contained
lysines with diglycyl adducts—typical remnants of ubiquitination
or modification with ubiquitin-like proteins after tryptic digestion.
They were confidentially identified on K25, K28, K41, K47, and
K50 (Figure S4F). However, no signal was seen when F17-HA
was immunoprecipitated and analyzed for conjugated ubiquitin
by immunoblot (data not shown). This suggested that ubiquiti-
nated F17 only accounted for a small fraction of the total F17
within MVs and was not the cause of the additional F17 bands
observed by immunoblot. The slower migrating F17 bands also
occurred when codon-optimized F17-HA was transiently ex-
pressed in HeLa cells (data not shown). It is possible that they
represent SDS-resistant F17 oligomers.
It was previously reported that F17 was phosphorylated on
serines 53 and 62 (Wickramasekera and Traktman, 2010). In
MVs, we only detected phosphorylation of F17 S53, S2, and
S40, while S62 phosphorylation was never observed, despite
the good coverage. Perhaps F17 phosphorylated on S62 is not
packaged into MVs or only occurs when S53 is not available.
Curiously, although K50 and S53 (as well as K47 in the case of
miscleaved peptides) are within the same peptide, phosphoryla-
tion and diglycyl adducts on lysines were never observed on the
same peptide. This raises the possibility that phosphorylation
and ubiquitination of F17 are mutually exclusive.
Consistent with ubiquitination of F17 after entry, we found
that a fraction of cell-associated F17-HA ran as a high-
molecular-weight smear in MG-132-treated cells 3 hr post
infection (Figure S4E). However, due to the small amount of
cell-associated F17-HA that could be recovered by immuno-
precipitation, we could not determine if this smear was ubiquiti-
nated F17.
To assess if stabilization of F17 by MG-132 correlated with
the accumulation of intact LBs, host cells were infected with
WR EGFP-F17 VP8-mCherry in the presence of ActD and MG-
132. Under these conditions, there was a clear increase in the
number of cytoplasmic EGFP-F17 spots devoid of VP8-mCherry
(Figure 4D).
These results indicated that LBs dissociate from the core
as distinct entities that are subsequently disassembled in host
cells by proteasome activity. As F17 was degraded by protea-
somes in the same time frame, it is tempting to speculate that
degradation of the abundant LB protein F17 triggers LB disinte-
gration. That the number of cores still exceeded the number of
F17 spots when proteasomes were inhibited suggested that pro-
teasome activity may not be the sole contributing factor to LB
disassembly.
The VACV Dual-Specificity Phosphatase VH1 and
Glutaredoxin G4 Are Located in LBs
In infected cells, F17 is phosphorylated by cellular proline-
directed kinases and dephosphorylated by the viral dual-speci-
ficity phosphatase VH1 (Liu et al., 1995; Wickramasekera and
Traktman, 2010). MVs lacking VH1 or those incorporating a
F17 mutant that cannot be phosphorylated are impaired in early
gene expression (Liu et al., 1995; Wickramasekera and Trakt-
man, 2010). The functional relationship between F17 and VH1
suggested that these proteins may be in close proximity within
virions. While VH1 has been shown to be present in cores gener-
ated in vitro (Liu et al., 1995), its precise localization within these
subviral structures has not been determined.
We generated a virus expressing an HA-tagged version of VH1
and verified by immunoblot that VH1-HA was incorporated into
MVs (Figure S5C). Under nonreducing conditions, a fraction of
VH1 ran as high-molecular-weight bands, suggesting the protein
is partly engaged in intermolecular disulfide bonds. We next
analyzed VH1-HA localization by immunogold labeling and EM.
MVs of WR VH1-HA were artificially fused to HeLa cells, allowing
us to analyze the subviral localization of VH1 in intact MVs at the
cell surface and in virus structures shortly after fusion (Figures
5A, 5B, 5E, S5A, and S5B). In bound MVs, an average of 4.1
gold particles was found within the region of LBs, while only
Figure 3. F17 Is Localized to Lateral Bodies
(A–G) MVs ofWR EGFP-F17 (A–C) or WR EGFP-A4 (E–G) were bound to HeLa cells on ice (moi 100), treated with pH 5medium at 37C for 5 min, and incubated in
full medium for 30 min at 37C. Cells were fixed and subjected to cryosectioning and anti-GFP immunogold labeling. (A) and (E) show typical thin sections;
representative MVs and cytosolic cores are displayed in (B)/(F) and (C)/(G), respectively. Arrows indicate cytosolic cores. (D) MVs and cores in thin sections were
counted and scored for immunogold labeling of GFP fusion proteins; n = 100 for each. Scale bars, 500 nm (A and E) and 100 nm (B, C, F, and G).
(H–J) Representative micrographs of WR WT MVs (H), in vitro cores (I), and in vitro cores treated with trypsin (J) subjected to cryosectioning and immunogold
labeling with anti-F17. Scale bar, 100 nm.
(K) Average number of gold particles in the respective subviral locations ± SD; n = 50 virions; n/a, not applicable.
(L) WR WT MVs were bound to HeLa cells on ice (moi 100), treated with pH 5 medium at 37C for 5 min, fixed, and subjected to cryosectioning and anti-F17
immunogold labeling. Arrows indicate cytosolic cores; a separate lateral body from (I) is shown in the inset at the same scale.
See also Figure S3.
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0.2 gold particles were found over the core. In addition, immuno-
gold labeling corresponding to VH1was found in LBs close to the
plasma membrane after acid-induced fusion, with little staining
associated with released cores. These results indicated that
VH1, like F17, is a component of VACV LBs.
In search of additional LB components, we analyzed three
additional viral enzymes known to be incorporated into MVs:
the viral kinase B1 as well as G4 and E10, two redox enzymes
involved in the formation of cytosolic disulfide bonds during virus
assembly (Banham and Smith, 1992; Senkevich et al., 2000;
White et al., 2000). Using recombinant viruses that express
and subsequently package the HA-tagged variants of the
respective proteins (Senkevich et al., 2002; White et al., 2000;
data not shown), we performed experiments as described for
VH1-HA. These revealed that HA-G4 was predominantly found
Figure 4. Lateral Bodies Can Be Visualized and Are Stabilized by the Proteasome Inhibitor MG-132
(A) Representative images of WR VP8-mCherry EGFP-F17 MVs bound to coverslips, stained for the MV membrane protein L1, and analyzed by confocal
microscopy. Scale bar, 10 mm.
(B–D)WRVP8-mCherry EGFP-F17MVswere bound toHeLa cells on ice (moi 15). Cells were either fixed directly (B) or incubated at 37C for 3 hr in the presence of
ActD (C) or ActD and 25 mM MG-132 (D). Samples were analyzed by confocal microscopy, and maximal projections of representative Z-stacks are presented.
Examples of MVs (arrows), cytosolic cores (closed arrowheads), and free LBs (open arrowheads) are highlighted in the insets. Scale bar, 10 mm.
(E) WR F17-HAMVs were bound to HeLa cells in the cold (moi 10), treated with pH 5medium at 37C for 5 min, and harvested directly or incubated in full medium
with ActD or ActD and MG-132 for 2 hr at 37C. During harvest, bound MVs were removed with trypsin. Cells were lysed in SDS sample buffer and proteins
analyzed by SDS-PAGE and immunoblot with anti-HA, anti-VP8, anti-4b, and anti-tubulin.
See also Figure S4.
Figure 5. VH1 and G4 Localize to Lateral
Bodies
(A–D) WR VH1-HA MVs (A and B) or WR G4-HAi
MVs produced in the presence of 50 mM isopropyl
b-D-1-thiogalactopyranosid (IPTG) (C and D) were
bound to HeLa cells on ice (moi 100) and treated
with pH 5 medium at 37C for 5 min. Cells were
fixed and subjected to cryosectioning and anti-HA
immunogold labeling. Representative bound MVs
are displayed in (A) and (C); MVs having just
undergone fusion with the plasma membrane are
shown in (B) and (D). Arrows indicate LBs; scale
bars, 100 nm.
(E) Average number of gold particles in the
respective subviral locations ± SD after anti-HA
immunogold labeling of bound WR VH1-HA, WR
G4-HAi (+IPTG), and WR E10-HA A2.5-V5 MVs
(n = 50, 70, and 69 MVs).
See also Figure S5.
in LBs (Figures 5C, 5E, and S5D). Consis-
tent with the literature, E10-HA mainly
localized to the MV membrane (Figure 5E
and S5E), although it acts upstream of G4
in the redox cascade during morphogen-
esis (Senkevich et al., 2000). The localiza-
tion of HA-Strep-B1 could not unambigu-
ously be determined, likely due to the low
abundance of this kinase in MVs (Chung
et al., 2006; Resch et al., 2007; data not
shown).
Thus, immunogold labeling of recombi-
nant viruses in combination with electron
microscopy allowed us to identify two additional LB compo-
nents: the viral enzymes VH1 and G4.
The Immunomodulatory Activity of VH1 Depends on
Proteasome Activity
The VH1 associated with incoming virus catalyzes the dephos-
phorylation of the tyrosine-phosphorylated transcription factor
STAT1 (p-STAT1) (Najarro et al., 2001). STAT1 is phosphorylated
in response to interferon g (IFNg) and imported to the nucleus as
homodimers, where it mediates the transcription of antiviral and
antimicrobial genes (MacMicking, 2012).
Using STAT1 phosphorylation after IFNg-treatment as a
readout for VH1 activity, we asked if LBs have to be disas-
sembled to render VH1 biologically active. HeLa cells infected
with wild-type (WT) VACV (or left uninfected) were stimulated
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for 30 min with IFNg at 1 hr post infection. Samples were then
assayed for STAT1 phosphorylation by flow cytometry and
immunoblot analysis (Figures 6A–6D). In the absence of infec-
tion, IFNg treatment increased the p-STAT1 signal 5-fold.
Infection with WT VACV at a low multiplicity of infection (moi)
prevented STAT1 phosphorylation almost completely (1.2-fold
induction) (Figures 6A and 6C). This effect was reverted when
VH1 activity was inhibited with orthovanadate, as previously
described (Najarro et al., 2001).
To determine if LB disassembly was required for VH1 activity,
p-STAT1 levels were assessed in cells infected at an moi of 2.5
in the presence of MG-132. The amount of phosphorylated
STAT1 was increased by 5-fold, indicating that VH1 could not
dephosphorylate p-STAT1 in the presence of MG-132 (Figures
6B and 6C). This suggested that proteasome activity was
required for full VH1 activity. Inhibition of viral and cellular gene
Figure 6. VH1Activity Requires Proteasome
Activity
WRWT MVs (moi 2.5 or as indicated) were bound
to HeLa cells in the cold and incubated for 1 hr at
37C in the presence of the indicated inhibitors
(0.75% DMSO (untreated), 5 mg/ml ActD, 25 mM
MG-132, or 2 mM orthovanadate [OV]). Cells were
subsequently stimulated with IFNg in the presence
of inhibitors for 30 min at 37C, harvested, and
processed for flow cytometry (A–C), immunoblot
(D), or fluorescence microscopy (E–J).
(A–C) p-STAT1 levels were quantified by fluo-
rophore-labeled anti-p-STAT1 and flow cy-
tometry. Representative histograms are shown in
(A) and (B); average fold increase of p-STAT1
levels upon IFNg treatment (geometric means) ±
SEM from three independent experiments (C).
(D) Cells were lysed and analyzed by SDS-PAGE
and immunoblot using the indicated antibodies.
(E–J) Cells were fixed, permeabilized, and stained
for STAT1, DNA, and filamentous actin. Samples
were analyzed by wide-field fluorescence micro-
scopy. Scale bar, 25 mm.
See also Figure S6.
transcription with ActD also partly
rescued IFNg-dependent STAT1 phos-
phorylation by 4.5-fold (Figure 6C). This
was in linewith the requirement for cellular
gene expression, as previously described
(Najarro et al., 2001), or may hint at alter-
native mechanisms to prevent STAT1
phosphorylation that dependonearly viral
genes. Early expression of VH1 during
infection would explain this phenotype,
but the protein was not expressed before
DNA replication (Rosel et al., 1986; data
not shown). Importantly, orthovanadate,
likeActD, completely shut downearly viral
gene expression, whereas MG-132
reduced it only moderately (Figure S6E).
Total STAT1 levels remained constant un-
der all conditions (Figure 6D).
At higher mois, the ability of MG-132 and ActD to prevent the
VACV-mediated reduction in STAT1 phosphorylation was over-
come. However, when combined, the two inhibitors prevented
all viral effects on IFNg-induced STAT1 phosphorylation, sug-
gesting the drugs target independent processes.
Consistent with its role as an interferon-inducible transcription
factor, STAT1 rapidly undergoes nuclear import upon activation.
To test if STAT1 phosphorylation correlated with its nuclear
translocation and thus biological function, we investigated the
subcellular localization of STAT1 during VACV infection using
fluorescence microscopy (Figures 6E–6J). In untreated cells,
STAT1was found throughout the cytosol; upon IFNg stimulation,
STAT1 localized predominantly in the nucleus, as expected.
When WT VACV-infected cells were treated with IFNg, STAT1
was found throughout the cytosol, indicating that STAT1 phos-
phorylation and nuclear import were counteracted by VH1. In
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cells infected in the presence of MG-132, nuclear import of
STAT1 was restored, consistent with the impairment of VH1-
mediated STAT1 dephosphorylation.
Collectively, these results indicated that VH1-mediated
dephosphorylation of STAT1 was dependent on proteasome
function in host cells. Given that VH1 is active in the absence
of any cofactors (Koksal and Cingolani, 2011; Liu et al., 1995),
it is probable that the main role of proteasomes is to facilitate
LB disassembly. This in turn may result in the liberation of
VH1, allowing it to fulfill its effector function prior to early gene
expression.
DISCUSSION
After penetration into the cytosol of host cells, incoming viruses
and viral capsids have to undergo additional steps before repli-
cation can start. With their complex structure and exceptional
stability, poxviruses have evolved a stepwise disassembly pro-
gram dependent on both viral and cellular factors and cues.
Our results indicate that the first step in this process, core acti-
vation, involves the dissolution of a network of disulfide cross-
linked core proteins, which coincides with core expansion and
loss of LB core interaction. We identified three poxvirus LB com-
ponents, among which the dual-specificity phosphatase VH1
exerts an immunomodulatory effector function in the host cell
cytosol. We found that both LB disassembly and the phospha-
tase activity of VH1 require functional proteasomes. We hypoth-
esize that proteasome-mediated release of VH1 from LBs allows
VACV to counteract the antiviral response of type II interferons
immediately after penetration—at a time when incoming virus
particles have yet to undergo gene expression and are likely
particularly vulnerable.
Using different EM techniques, we found that, during activa-
tion, cores lost their biconcave shape and expanded so that
the internal volume increased by 44%. It is tempting to specu-
late that reduction of disulfide-bonded 4b and possibly other
proteins during activation is required for these morphological
changes. Consistent with this, in vitro cores in which all tested
disulfide bonds are reduced (data not shown) resemble activated
cores. These changes may facilitate the initiation of early tran-
scription. Along these lines, in vitro transcription from cores re-
quires the presence of reducing agents (Munyon et al., 1967).
We found that two RNA polymerase subunits were disulfide-
bonded; perhaps their reduction activates the RNA polymerase
during infection.
Concomitantly with the release of cores into the cytosol, the
two proteinaceous LBs of previously unknown composition
and function dissociated from the core. Apparently, the interac-
tions that maintain LB association with the core wall, as
observed in in vitro cores, were lost. Because the LBs were left
behind where the viral and the cellular membranes fused, the in-
teractions with the viral membrane seemed to remain, at least
transiently, intact.
In this study, we identified the viral protein F17 as onemajor LB
component. It was previously described as a core or even DNA-
binding protein (Ichihashi et al., 1984). Previous studies showed
that it interacts with itself and other viral proteins (Mercer and
Traktman, 2005; Wickramasekera and Traktman, 2010) and
that it localized throughout immature virions and at the core
rim in MVs (Traktman et al., 2000). In the absence of F17,
VACV exhibits morphogenesis defects: only few aberrant virions
were formed that lacked visible LBs (Wickramasekera and Trakt-
man, 2010). These findings are consistent with partitioning of F17
into LBs during morphogenesis.
When followed by fluorescence microscopy, we found that
LBs rapidly disappeared as recognizable particles after core
release and that this correlated with proteasome-dependent
degradation of F17. The observed reduction of disulfide-bonded
F17 may contribute to LB disassembly as well, although the LBs
of in vitro coreswith fully reduced F17 (data not shown) appeared
stable.While F17may have a direct function in host cells, its rapid
degradation rather suggests a role as the LB scaffold protein.
We also identified a second LB component, the dual-speci-
ficity phosphatase VH1, of which 200 molecules are packaged
per MV (Liu et al., 1995). VH1 is conserved in all poxviruses (Iyer
et al., 2006), is essential for the viral life cycle (Liu et al., 1995),
and has several viral substrates, including F17, A14, and A17
(Derrien et al., 1999; Liu et al., 1995; Traktman et al., 2000). Immu-
nomodulatory functions of VH1 include the dephosphorylation of
the antiviral transcription factor STAT1 and possibly murine
STAT2 (Mann et al., 2008; Najarro et al., 2001). In our hands,
p-STAT2 levels after IFNa treatment of human cells were not
affected by VACV infection (data not shown). VACV replication
in several cell lines was sensitive to STAT1-dependent antiviral
gene expression induced by IFNg pretreatment (Terajima and
Leporati, 2005; Trilling et al., 2009). Additionally, treatment of
VACV-infected mice with IFNg significantly increased survival
(Liu et al., 2004). Collectively, this indicates that VACV needs to
interfere with the STAT1-mediated antiviral response for efficient
replication.
In our study, p-STAT1 served as a suitable substrate to
analyze VH1 activity. We could show that VH1 phosphatase ac-
tivity on p-STAT1 required functional proteasomes. Given that
LBs are stabilized in the presence of proteasome inhibitors and
VH1 activity does not require any cofactors (Koksal and Cingo-
lani, 2011), one attractive hypothesis is that incorporation of
VH1 in LBs renders the protein inactive and that VH1 has to be
released to be catalytically active. The VH1 inhibitor orthovana-
date did not lead to the accumulation of LBs (data not shown),
suggesting that VH1 activity is not required for LB disassembly.
The viral glutaredoxin G4 was identified as a second catalyti-
cally active LB component. Expressed late during infection, G4
is essential for virus morphogenesis (White et al., 2000). It is a
component of the VACV-encoded cytoplasmic disulfide-bond
formation cascade, consisting of itself, A2.5, and E10. As the
last enzyme of this cascade, G4 catalyzes disulfide bond forma-
tion in a number of viral membrane proteins, including F9, L1,
A21, A28, L5, H2, and A16 (Moss, 2012; Senkevich et al.,
2002, 2005). It is likely that E10, A2.5, and G4 also catalyze the
formation of disulfide bonds in core and LB proteins. G4 is pre-
dominantly packaged in its oxidized form (White et al., 2002).
Perhaps G4 oxidizes or reduces its natural substrates during or
after entry and may be involved in viral membrane fusion, core
activation, or the regulation of LB disassembly.
We concluded that poxvirus LBs serve to transport at least
one, and possibly more, effector proteins that act in host cells
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prior to viral gene expression. LBs thus comprise a delivery
mechanism, presumably conserved across the entire poxvirus
family (see Extended Discussion). A similar strategy is used by
herpes viruses, such as herpes simplex virus 1, which delivers
the virion host shutoff protein and other effectors into cells as
part of the tegument, a complex of proteins located inside the
particle but outside of the capsid (Smiley, 2004).
Given that the quantified LB components F17 and VH1 only
occupy 69%and 1%of the LBmass, respectively (see Extended
Experimental Procedures), one can assume the presence of an
extra ‘‘payload’’ of additional viral factors. Among these may
be viral enzymes that counteract pathogen recognition or modu-
late the host cell to facilitate virus replication. It is likely that LB-
resident proteins also contribute to the cooperativity of VACV
early gene expression (Stiefel et al., 2012), where LB proteins
could act on viral cores in trans. Interestingly, when the first 42
amino acids of F17 were fused to the reporter protein b-galacto-
sidase, the recombinant protein was incorporated into virions
and found to be catalytically active in newly infected cells in
the absence of viral gene expression (Huang et al., 1988).
Perhaps the identification of LB packaging signals will facilitate
identification of additional poxvirus effectors.
Deciphering the molecular components and functions of LBs
will contribute to a deeper understanding of the early stages of
the viral life cycle and probably help further elucidate how poxvi-
ruses modulate the host immune system. Moreover, identifica-
tion of LB packaging signals may allow for artificial targeting of
foreign proteins into recombinant poxviruses. Thus, LBs may
open attractive possibilities to deliver proteins to cells, to
improve poxvirus-based vaccines, and to engineer more potent
oncolytic poxviruses.
EXPERIMENTAL PROCEDURES
Cell Lines
BSC-40 (African green monkey) and HeLa (human) cells were cultivated in
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) supplemented
with 10% heat-inactivated fetal calf serum (FCS), glutamax, and penicillin-
streptomycin; for BSC-40 cells, nonessential amino acids and sodium pyru-
vate were added in addition.
Viruses
Recombinant vaccinia viruses were generated based on VACV strain WR by
transfecting infected cells with plasmids containing genomic viral sequences,
as described elsewhere (Mercer and Helenius, 2008; see Extended Experi-
mental Procedures for details on the generation of the respective virions).
WR EGFP-A4 was described previously as WR EGFP-A5 (Schmidt et al.,
2011); WR HA-G4i (vG4Li) (White et al., 2000) and WR E10-HA A2.5-V5
(vE10R-HA/A2.5L-V5) (Senkevich et al., 2002) were kind gifts of Bernard
Moss (National Institutes of Health). MVs were produced in BSC-40 cells
and purified from cytoplasmic lysates, as described elsewhere (Mercer and
Helenius, 2008).
Preparation of In Vitro Cores and Other Subviral Particles
In vitro cores were generated by incubating MVs with 1% NP-40 and 50 mM
DTT in 10 mM Tris (pH 9.0) for 30 min at 37C. Cores were sedimented for
1 hr at 16,000 g and 4C in a tabletop centrifuge and resuspended in 1 mM
Tris (pH 9.0). To partially remove LBs, the in vitro core pellet was resuspended
in PBS and treated with 20 mg/ml trypsin at 37C for 15 min. The trypsin digest
was stoppedwith 200 mg/ml aprotinin on ice and virions processed for electron
microscopy.
Antibodies and Reagents
A complete list of the used antibodies and reagents is presented in the
Extended Experimental Procedures.
Immunoblot
Samples to be analyzed by immunoblot were boiled in SDS sample buffer with
100 mM DTT for 5 min at 95C. To analyze the redox state of viral proteins,
samples were alkylated with 20 mM N-ethylmaleimide (NEM) prior to denatur-
ation and boiled in SDS sample buffer with or without DTT. Proteins were sepa-
rated on discontinuous SDS-PAGE gels (10% or 15%) or 4%–12% NuPAGE
gels (Invitrogen), transferred to nitrocellulose membranes, and analyzed using
rabbit anti-4b, anti-4a, anti-A4, anti-VP8, anti-F17, mouse anti-HA (all 1:1,000),
rabbit anti-STAT1 (1:500), or rabbit anti-p-STAT1 (1:1,000) in combination with
horseradish peroxidase (HRP)-coupled secondary antibodies (1:5,000).
Infection Experiments—Immunofluorescence and Electron
Microscopy, Immunoblot
For infection experiments, the indicated amount of MVs were bound to HeLa
cells in the cold for 1 hr. Cells were subsequently incubated in full medium
at 37C for the denoted time and processed for immunofluorescence micro-
scopy or different electron microscopy methods. When infection experiments
were performed in the presence of drugs, drugs were present during binding
and incubation. In some cases, artificial fusion with the plasma membrane
was induced after binding by a 5 min treatment with full medium containing
30 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.0, at 37C. For
some immunoblot experiments, bound virions were removed by incubation
of cells in 0.25% trypsin (Invitrogen) for 10 min followed by extensive washing
in 7% FCS/PBS.
Fluorescence Microscopy
For immunofluorescence microscopy, cells were fixed with 4% formaldehyde
(FA) and stained with anti-L1 (0.54 mg/ml) or anti-STAT1 (1 mg/ml) and fluoro-
phore-coupled goat secondary antibodies (1:1,000). Where indicated, actin
was stained with fluorophore-coupled phalloidin (1:100) and DNA with
Hoechst 33258 (1:10,000). To analyze MVs or in vitro cores, dilutions of the
respective samples were bound to coverslips for 20 min, washed, and pro-
cessed as above. Samples were recorded by confocal microscopy using a
Zeiss LSM510Meta system with a 100X 1.4 numerical aperture (NA) objective.
Sample Processing for Epoxy Embedding EM
Infected cells were fixed and processed for epoxy embedding EM as
described elsewhere (Bleck et al., 2010; McDonald, 1984) (see Extended
Experimental Procedures for details).
Sample Processing for Immunogold EM According to Tokuyasu
Samples were fixed in 4% FA, 0.1% glutaraldehyde (GA) in 60 mM PIPES,
25 mM HEPES, 10 mM EGTA, and 1 mM MgCl2 (pH 6.9) (PHEM buffer, pH
6.9) (Schliwa et al., 1981). Cells were scraped and sedimented at 500 g; virions
or subviral structures were sedimented at 10,500 g. Cryosectioning and immu-
nolabeling were performed as described elsewhere (Slot and Geuze, 2007;
Tokuyasu, 1973; see Extended Experimental Procedures for details). In brief,
ultrathin sections (50–60 nm) from gelatin-embedded and frozen cell pellets
were obtained using an FC7/UC7-ultramicrotome (Leica).
For immunolabeling, cryosections were thawed and incubated with anti-F17
(1:400), anti-GFP (2.5 mg/ml), anti-DNA (0.33 mg/ml), or anti-HA (2 mg/ml).
Mouse primary antibodies were detected with polyclonal rabbit anti-mouse
immunoglobulin Gs (IgGs) (0.5 mg/ml). All samples were incubated with 5 or
10 nm protein A gold (PAG) (1:60, CMC), as described (Griffiths et al., 1993;
Slot and Geuze, 2007), and stained/embedded in 4% uranyl acetate/2%
methyl cellulose mixture (ratio 1:9) (Tokuyasu, 1980).
Analysis of Subviral Structures from Electron Micrographs
Thin sections from samples prepared after Tokuyasu (1973) were used for all
measurements. To determine the length and width of cores, cores were traced
in ImageJ, and processed in Matlab using Dynamo (Castan˜o-Dı´ez et al., 2012)
with an adapted algorithm as follows: The core length was defined as the
greatest distance between any two points on a single core outline and
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determined the main axis. This axis was divided into three equal segments,
and for each, the maximal and minimal widths perpendicular to the main
axis were measured. The minimal width in the central segment was used to
compare core widths among different cores; box plots were created using
GraphPad Prism (GraphPad Software). The core volume was approximated
based on the core area (A, determined using ImageJ) as described by Cyrklaff
et al. (2007): V = (sqrt[A/p])34p/3 (n = 100).
Analysis of STAT1 Phosphorylation and Localization
To analyze STAT1 phosphorylation or localization, the indicated amounts of
WR WT MVs (+ inhibitors) were bound to pretreated HeLa cells at 4C for
1 hr and cells were incubated at 37C for 1 hr (+ inhibitors). Cells were fed
withmedium containing drugs and 1,000 U/ml IFNg and harvested 30min after
stimulation at 37C. For immunoblot analysis, cells were solubilized in SDS
sample buffer with phosphatase inhibitors and analyzed as above. To quantify
STAT1 phosphorylation by flow cytometry, cells were stained with Alexa Fluor
647 anti-P-STAT1 (1:10) (Schulz et al., 2012). Cells were analyzed using a BD
FACSCalibur flow cytometer and the FlowJo software package. For immuno-
fluorescence staining of STAT1, cells were fixed and processed as above and
analyzed by wide field fluorescence microscopy using an Olympus Cell^ R
imaging station with a 60X 1.4 NA objective.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Discussion, Extended Experi-
mental Procedures, six figures, and two tables and can be found with this
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